Celiac disease and drug absorption: Implications for cardiovascular therapeutics

Ian Wang, Ingrid Hopper

Research output: Contribution to journalLetterOther

2 Citations (Scopus)

Abstract

Introduction Current prevalence of celiac disease is estimated to be around 1 in the general population of Europe [1] and the United States [2]. Cardiovascular disease has an even higher prevalence and is the leading cause of death in these regions, causing 46 of all deaths in the European Union [3] and 32 in the United States [4]. Given that many cardiovascular drugs are orally administered, absorption of these drugs may be significantly altered in celiac disease.
Original languageEnglish
Pages (from-to)253 - 256
Number of pages4
JournalCardiovascular Therapeutics
Volume32
Issue number6
DOIs
Publication statusPublished - 2014

Cite this

@article{198f6e3341e8454b80ea8b5b854dd4cf,
title = "Celiac disease and drug absorption: Implications for cardiovascular therapeutics",
abstract = "Introduction Current prevalence of celiac disease is estimated to be around 1 in the general population of Europe [1] and the United States [2]. Cardiovascular disease has an even higher prevalence and is the leading cause of death in these regions, causing 46 of all deaths in the European Union [3] and 32 in the United States [4]. Given that many cardiovascular drugs are orally administered, absorption of these drugs may be significantly altered in celiac disease.",
author = "Ian Wang and Ingrid Hopper",
year = "2014",
doi = "10.1111/1755-5922.12094",
language = "English",
volume = "32",
pages = "253 -- 256",
journal = "Cardiovascular Therapeutics",
issn = "1755-5914",
publisher = "Wiley-Blackwell",
number = "6",

}

Celiac disease and drug absorption: Implications for cardiovascular therapeutics. / Wang, Ian; Hopper, Ingrid.

In: Cardiovascular Therapeutics, Vol. 32, No. 6, 2014, p. 253 - 256.

Research output: Contribution to journalLetterOther

TY - JOUR

T1 - Celiac disease and drug absorption: Implications for cardiovascular therapeutics

AU - Wang, Ian

AU - Hopper, Ingrid

PY - 2014

Y1 - 2014

N2 - Introduction Current prevalence of celiac disease is estimated to be around 1 in the general population of Europe [1] and the United States [2]. Cardiovascular disease has an even higher prevalence and is the leading cause of death in these regions, causing 46 of all deaths in the European Union [3] and 32 in the United States [4]. Given that many cardiovascular drugs are orally administered, absorption of these drugs may be significantly altered in celiac disease.

AB - Introduction Current prevalence of celiac disease is estimated to be around 1 in the general population of Europe [1] and the United States [2]. Cardiovascular disease has an even higher prevalence and is the leading cause of death in these regions, causing 46 of all deaths in the European Union [3] and 32 in the United States [4]. Given that many cardiovascular drugs are orally administered, absorption of these drugs may be significantly altered in celiac disease.

UR - http://onlinelibrary.wiley.com.ezproxy.lib.monash.edu.au/doi/10.1111/1755-5922.12094/abstract

U2 - 10.1111/1755-5922.12094

DO - 10.1111/1755-5922.12094

M3 - Letter

VL - 32

SP - 253

EP - 256

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

SN - 1755-5914

IS - 6

ER -